Tej Lalvani, the Dragons' Den investor, is poised to sell his family's vitamin empire Vitabiotics to private-equity firm Bain Capital for a reported £900 million, according to City insiders. The deal, negotiated over recent weeks, is expected to close in the coming days, ending Lalvani's decade-long leadership of the UK's top mulitvitamin provider. Vitabiotics, founded by Lalvani's father more than 50 years ago, has grown revenue from £101 million to £195.6 million under his tenure and now sells in over 100 countries.

From Forklift Operator to £195.6 Million Revenues: Tej Lalvani's Decade at the Helm

Tej Lalvani started his career at Vitabiotics as a forklift operator in the company's warehouse, the source reports. Over the following years,he worked through every department—from drug development to sales—while earning a pharmaceutical science degree across London, Germany and India. When he took over as CEO in 2015, the company's revenue stood at £101 million; by the time of the sale negotiations, it had nearly doubled to £195.6 million. Under his leadership, Vitabiotics launched flagship brands such as Wellwoman, Perfectil and Pregnacare, and secured endorsements from celebrities including Tess Daly , David Gandy and Davina McCall.

How Bain Capital Beat Blackstone in a Week of Intensive Talks

The sale process attracted two major private-equity firms: Bain Capital and Blackstone, the world's largest alternative asset manager, according to the source. In April, a preliminary exercise narrowed the field to these two bidders. Bain presented the most compelling offer, winning sole negotiation duties. Insiders note that while pricing has been agreed, the final contrat could still face hurdles, as the deal remains delicate. The £900 million price tag, if finalized, would set a new benchmark for UK consumer health company valuations.

The Unanswered Questions: Deal Timeline and Management Succession

Despite the report's details on the bidding process, several key points remain unconfirmed. The source does not specify when the deal will officially close beyond 'in the next few days.' Nor does it disclose whether Lalvani will remain involved with the company or step away entirely after the acquisition. Vitabiotics has not issued a formal statement, and Bain Capital has declined to comment publicly, the source says. These gaps leave investors and industry watchers guessing about the post-deal structure.

Why Vitabiotics' £900 Million Sale Echoes a Broader Trend in Consumer Health Exits

The Vitabiotics deal is the latest in a wave of private-equity acquisitions targeting niche consumer health brands in the UK, according to the source. High-profile entrepreneurs like Lalvani are monetizing their stakes at premium valuations,signaling to other mid-cap players in the nutrition sector that exits at such levels are viable. The report notes that the acquisition underscores the attractiveness of the vitamin niche to global investors seeking steady cash flow and growth potential. If Bain Capital succeeds,it will not only redistribute ownership of a household name but also reinforce the trend of family-run businesses transitioning to institutional ownership.